RESEARCH &RELATED - OTHER PROJECT INFORMATION - PROJECT SUMMARY/ABSTRACT This Core B facility will serve as a technical and scientific support unit for the three projects (1, 2, 3) of this Program Project. Its major goals involve: (1) the re-synthesis and scale-up of compounds in sufficient quantifies to address the in vitro and in vivo needs of the research laboratories involved in the four projects;all compounds will be evaluated in silico for their druggability properties as well (2) the testing of all new ligands for their affinities for the CB1 and CB2 cannabinoid receptors;(3) the testing of ligands for their abilities to bind irreversibly to CB1 and CB2;(4) the testing of a class of ligands for their abilities to act as substrates or inhibitors for the endocannabinoid deactivating enzymes, FAAH and MGL;(5) determining the functional properties of successful ligands initially in the cAMP assay;(6) determining the biochemical stabilities of ligands using liver microsomal preparations;(7) evaluation of a select group of novel ligands in mice for bioavailability and their ability to cross the blood brain barrier;and (8) evaluation of CB1 antagonists in vivo (mice) for their ability to antagonize the effects of an agonist. Compounds produced under the auspices of Core B will also be made available to other laboratories identified in this program project whose collaboration is at no cost to the grant.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
2P01DA009158-15A1
Application #
8742282
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2014-09-15
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Northeastern University
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02115
Hua, Tian; Vemuri, Kiran; Nikas, Spyros P et al. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature 547:468-471
Slivicki, Richard A; Xu, Zhili; Kulkarni, Pushkar M et al. (2017) Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biol Psychiatry :
Finlay, David B; Cawston, Erin E; Grimsey, Natasha L et al. (2017) G?s signalling of the CB1 receptor and the influence of receptor number. Br J Pharmacol 174:2545-2562
Ruehle, Sabine; Wager-Miller, James; Straiker, Alex et al. (2017) Discovery and characterization of two novel CB1 receptor splice variants with modified N-termini in mouse. J Neurochem 142:521-533
Dhopeshwarkar, Amey; Murataeva, Natalia; Makriyannis, Alex et al. (2017) Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists. J Pharmacol Exp Ther 360:300-311
Mallipeddi, Srikrishnan; Janero, David R; Zvonok, Nikolai et al. (2017) Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets. Biochem Pharmacol 128:1-11
Li, Ai-Ling; Carey, Lawrence M; Mackie, Ken et al. (2017) Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther 362:296-305
Dhopeshwarkar, Amey; Mackie, Ken (2016) Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway. J Pharmacol Exp Ther 358:342-51
Järbe, Torbjörn U C; LeMay, Brian J; Thakur, Ganesh A et al. (2016) A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and ?(9)-THC in rats. Pharmacol Biochem Behav 148:46-52
Hua, Tian; Vemuri, Kiran; Pu, Mengchen et al. (2016) Crystal Structure of the Human Cannabinoid Receptor CB1. Cell 167:750-762.e14

Showing the most recent 10 out of 192 publications